Successful ceftazidime-avibactam therapy in a patient with multidrug-resistant Pseudomonas aeruginosa infective endocarditis

Infection. 2022 Aug;50(4):1039-1041. doi: 10.1007/s15010-022-01834-7. Epub 2022 Apr 17.
No abstract available

Publication types

  • Letter

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Azabicyclo Compounds / pharmacology
  • Azabicyclo Compounds / therapeutic use
  • Ceftazidime / pharmacology
  • Ceftazidime / therapeutic use
  • Drug Combinations
  • Drug Resistance, Multiple, Bacterial
  • Endocarditis* / drug therapy
  • Humans
  • Microbial Sensitivity Tests
  • Pseudomonas Infections* / drug therapy
  • Pseudomonas aeruginosa

Substances

  • Anti-Bacterial Agents
  • Azabicyclo Compounds
  • Drug Combinations
  • avibactam, ceftazidime drug combination
  • Ceftazidime